Recent data from the HIMALAYA trial also showed superiority for the combination of durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA (cytotoxic T-lymphocyte-associated protein)-4) versus sorafenib in the first-line treatment of HCC, establishing an alternative option for atezolizumab/bevacizumab [16]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.